Drug updated on 11/16/2023
| Dosage Form | Injection (intravenous; 1,000 mcg/1 mL) |
| Drug Class | CD123-directed cytotoxins |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Elzonris (tagraxofusp-erzs) Prescribing Information. | 2022 | Stemline Therapeutics, Inc., New York, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Elzonris. | 2021 | EMA |
| Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. | 2020 | Hematology/Oncology Clinics of North America |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. | 2022 | Cancer management and research |
| Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. | 2020 | Blood Advances |